After the exploration of the anti-tumor mechanisms of the lysine demethylase 1A inhibitor in thyroid cancer, Zhang et al. confirmed via in vitro and in vivo study that the highly specific inhibitor GSK-LSD1 considerably slows down the spread of tumor growth and makes it more responsive to chemotherapy. Here, KDM1A is linked to thyroid gland carcinoma.